594 related articles for article (PubMed ID: 17114044)
1. The familial Parkinsonism gene LRRK2 regulates neurite process morphology.
MacLeod D; Dowman J; Hammond R; Leete T; Inoue K; Abeliovich A
Neuron; 2006 Nov; 52(4):587-93. PubMed ID: 17114044
[TBL] [Abstract][Full Text] [Related]
2. LRRK2 and neurodegeneration.
Santpere G; Ferrer I
Acta Neuropathol; 2009 Mar; 117(3):227-46. PubMed ID: 19142648
[TBL] [Abstract][Full Text] [Related]
3. The biology and pathobiology of LRRK2: implications for Parkinson's disease.
Moore DJ
Parkinsonism Relat Disord; 2008; 14 Suppl 2():S92-8. PubMed ID: 18602856
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.
Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD
Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043
[TBL] [Abstract][Full Text] [Related]
5. Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity.
Lin CH; Lin HI; Chen ML; Lai TT; Cao LP; Farrer MJ; Wu RM; Chien CT
Hum Mol Genet; 2016 May; 25(10):1965-1978. PubMed ID: 26931464
[TBL] [Abstract][Full Text] [Related]
6. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.
Lin X; Parisiadou L; Gu XL; Wang L; Shim H; Sun L; Xie C; Long CX; Yang WJ; Ding J; Chen ZZ; Gallant PE; Tao-Cheng JH; Rudow G; Troncoso JC; Liu Z; Li Z; Cai H
Neuron; 2009 Dec; 64(6):807-27. PubMed ID: 20064389
[TBL] [Abstract][Full Text] [Related]
7. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain.
Higashi S; Biskup S; West AB; Trinkaus D; Dawson VL; Faull RL; Waldvogel HJ; Arai H; Dawson TM; Moore DJ; Emson PC
Brain Res; 2007 Jun; 1155():208-19. PubMed ID: 17512502
[TBL] [Abstract][Full Text] [Related]
8. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells.
Plowey ED; Cherra SJ; Liu YJ; Chu CT
J Neurochem; 2008 May; 105(3):1048-56. PubMed ID: 18182054
[TBL] [Abstract][Full Text] [Related]
9. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.
Gaig C; Ezquerra M; Martí MJ; Valldeoriola F; Muñoz E; Lladó A; Rey MJ; Cardozo A; Molinuevo JL; Tolosa E
J Neurol Sci; 2008 Jul; 270(1-2):94-8. PubMed ID: 18353371
[TBL] [Abstract][Full Text] [Related]
10. Clinical genetics of Parkinson's disease and related disorders.
Wider C; Wszolek ZK
Parkinsonism Relat Disord; 2007; 13 Suppl 3():S229-32. PubMed ID: 18267241
[TBL] [Abstract][Full Text] [Related]
11. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration?
Gillardon F
J Neurochem; 2009 Sep; 110(5):1514-22. PubMed ID: 19545277
[TBL] [Abstract][Full Text] [Related]
12. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.
Giordana MT; D'Agostino C; Albani G; Mauro A; Di Fonzo A; Antonini A; Bonifati V
Mov Disord; 2007 Jan; 22(2):275-8. PubMed ID: 17149743
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau.
Taymans JM; Cookson MR
Bioessays; 2010 Mar; 32(3):227-235. PubMed ID: 20127702
[TBL] [Abstract][Full Text] [Related]
14. A dual inhibitor targeting HMG-CoA reductase and histone deacetylase mitigates neurite degeneration in
Lin CH; Lin HY; Fang JM; Chen CC
Aging (Albany NY); 2020 Nov; 12(24):25581-25598. PubMed ID: 33231564
[TBL] [Abstract][Full Text] [Related]
15. Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation.
Miklossy J; Qing H; Guo JP; Yu S; Wszolek ZK; Calne D; McGeer EG; McGeer PL
Acta Neuropathol; 2007 Sep; 114(3):243-54. PubMed ID: 17639429
[TBL] [Abstract][Full Text] [Related]
16. (R1441C) LRRK2 induces the degeneration of SN dopaminergic neurons and alters the expression of genes regulating neuronal survival in a transgenic mouse model.
Weng YH; Chen CY; Lin KJ; Chen YL; Yeh TH; Hsiao IT; Chen IJ; Lu CS; Wang HL
Exp Neurol; 2016 Jan; 275 Pt 1():104-15. PubMed ID: 26363496
[TBL] [Abstract][Full Text] [Related]
17. Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2.
Martí-Massó JF; Ruiz-Martínez J; Bolaño MJ; Ruiz I; Gorostidi A; Moreno F; Ferrer I; López de Munain A
Mov Disord; 2009 Oct; 24(13):1998-2001. PubMed ID: 19735093
[TBL] [Abstract][Full Text] [Related]
18. 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.
Lavalley NJ; Slone SR; Ding H; West AB; Yacoubian TA
Hum Mol Genet; 2016 Jan; 25(1):109-22. PubMed ID: 26546614
[TBL] [Abstract][Full Text] [Related]
19. Leucine-rich repeat kinase 2 exacerbates neuronal cytotoxicity through phosphorylation of histone deacetylase 3 and histone deacetylation.
Han KA; Shin WH; Jung S; Seol W; Seo H; Ko C; Chung KC
Hum Mol Genet; 2017 Jan; 26(1):1-18. PubMed ID: 27798112
[TBL] [Abstract][Full Text] [Related]
20. The role of the LRRK2 gene in Parkinsonism.
Li JQ; Tan L; Yu JT
Mol Neurodegener; 2014 Nov; 9():47. PubMed ID: 25391693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
